轴丝动力蛋白中链基因1在肺腺癌中低表达且抑制肺腺癌细胞侵袭能力

张琳; 王雪婷; 王晓栋; 王玉; 李春涛; 尹崇高; 李洪利

doi:10.16098/j.issn.0529-1356.2021.02.012

PDF(6127 KB)

解剖学报 ›› 2021, Vol. 52 ›› Issue (2) : 237-243. DOI: 10.16098/j.issn.0529-1356.2021.02.012

肿瘤生物学

轴丝动力蛋白中链基因1在肺腺癌中低表达且抑制肺腺癌细胞侵袭能力

张琳¹ 王雪婷¹ 王晓栋¹ 王玉¹ 李春涛¹ 尹崇高²李洪利^3*

作者信息 +

Lower expression of dynein axonemal intermediate china 1 in lung adenocarcinoma and inhibits the invasion of lung adenocarcinoma cells

ZHANG Lin¹ WANG Xue-ting¹ WANG Xiao-dong¹ WANG Yu¹ LI Chun-tao¹ YIN Chong-gao² LI Hong-Li^3*

Author information +

文章历史 +

摘要

目的探讨轴丝动力蛋白中链基因1（DNAI1）在肺腺癌（LUAD）中的表达情况以及对肺腺癌侵袭能力的影响。方法微阵列基因芯片筛选肺腺癌组织(3例)与癌旁组织（3例）的差异表达基因；聚类热图(heatmap)、火山图（volcano plot）展示筛选后mRNA的表达和分布情况；利用DAVID数据库进行基因本体论（GO）和京都基因与基因组百科全书（KEGG）分析； STRING数据库和Cytoscape 3.6.1软件进行蛋白相互作用（PPI）分析并筛选核心基因（Hub基因)；结合DEGs、Ualcan数据库中各Hub基因在肺腺癌中的差异表达情况选择目的基因DNAI1；Real-time PCR、Western blotting检测DNAI1在人正常肺上皮细胞系BEAS-2B和肺腺癌细胞系H1299、A549中的表达情况；过表达DNAI1后观察细胞形态学变化；侵袭实验检测对A549细胞侵袭能力的影响。结果基因芯片结果筛选出86个上调基因和396个下调基因；差异基因参与RNA聚合酶Ⅱ启动子转录的正调控，凋亡过程的负调控，蛋白结合等功能，在胞内广泛分布，与代谢途径和癌症相关途径等信号通路有密切联系；DEGs和Ualcan数据库显示，筛选出的10个Hub基因中，DNAI1在肺腺癌组织中下调且差异表达较为显著；Real-time PCR和Western blotting结果显示，相较于人正常肺上皮细胞系BEAS-2B，DNAI1在肺腺癌细胞系H1299、A549中低表达；过表达DNAI1后A549细胞变圆，并有少数脱落；侵袭实验结果表明，过表达DNAI1后A549细胞侵袭能力显著降低。结论 DNAI1在肺腺癌中低表达且抑制肺腺癌细胞侵袭能力。

Abstract

Objective To investigate the expression of dynein axonemal intermediate chain 1(DNAI1) in lung adenocarcinoma(LUAD) and its influence on invasive ability of lung adenocarcinoma. Methods Microarray gene chip analysis was used to screen different expression genes in lung adenocarcinoma(3 samples) and adjacent normal tissues(3 samples); Heatmap and volcano plot were performed demonstrate the mRNA expression and distribution after screening; DAVID database used for Gene Ontology(GO) and Kyoto Encyclopedia of Genes of Genomes(KEGG) analysis; STRING database and Cytoscape 3.6.1 software for protein-protein interaction (PPI) analysis and screening of Hub genes; Objective genes were selected based on the differential expression of each Hub gene in lung adenocarcinoma in DEGs and Ualcan database ; Real-time PCR and Western blotting were used to detect the expression of DNAI1 in BEAS-2B, H1299 and A549; observe the morphological changes after DNAI1 overexpression; Transwell invasion assay was used to detect the change of invasion ability of A549 cells after DNAI1 overexpression. Results The microarray result showed that there were 86 up-regulated genes and 396 down-regulated genes; different genes were involved in the RNA polymerase Ⅱ promoter positive regulation of transcription, apoptosis process of negative regulation, protein binding, and other functions, widely distributed within the cell, and associated with the metabolic pathway, cancer and other signal pathways were closely related; DEGs database and Ualcan database showed that DNAI1 was the most downregulated among Hub genes in LUAD; the result of Real-time PCR and Western blotting showed that DNAI1 had lower expression in H1299 and A549 compared with BEAS-2B; after DNAI1 overexpression, A549 cells became round and a few shed off; invasion assay showed that the invasion ability of A549 cells was significantly reduced. Conclusion DNAI1 has a lower expression and inhibits the ability of invasion in LUAD, and this study can provide a potential molecular target and provide a theoretical basis for targeted therapy of LUAD.

导出引用

张琳王雪婷王晓栋王玉李春涛尹崇高李洪利. 轴丝动力蛋白中链基因1在肺腺癌中低表达且抑制肺腺癌细胞侵袭能力[J]. 解剖学报. 2021, 52(2): 237-243 https://doi.org/10.16098/j.issn.0529-1356.2021.02.012

ZHANG Lin WANG Xue-ting WANG Xiao-dong WANG Yu LI Chun-tao YIN Chong-gao LI Hong-Li. Lower expression of dynein axonemal intermediate china 1 in lung adenocarcinoma and inhibits the invasion of lung adenocarcinoma cells[J]. Acta Anatomica Sinica. 2021, 52(2): 237-243 https://doi.org/10.16098/j.issn.0529-1356.2021.02.012

中图分类号： R734.1

参考文献

［1］ Siegel RL, Miller KD. Cancer statistics［J］. CA Cancer J Clin, 2019,69(1): 7-34.

［2］ Siegel RL, Miller KD. Cancer statistics［J］. CA Cancer J Clin, 2018,68(1): 7-30.

［3］ Fan X, Zhang X, Wang H. Reevaluation of survival and prognostic factors in pathologic stage IA lung adenocarcinoma by the new 2009 TNM classification［J］. Tumour Biol, 2014, 35(6): 5905-5910.

［4］ Djakow J, Svobodová T, Hrach K, et al. Effectiveness of sequencing selected exons of DNAH5 and DNAI1 in diagnosis of primary ciliary dyskinesia［J］. Pediatr Pulmonol, 2012, 47(9):864-875.

［5］ Peng Y, Chen Z, Guan WJ, et al. Downregulation and aberrant localization of forkhead box j1 in allergic nasal mucosa［J］.Int Arch Allergy Immunol, 2018, 176(2):115-123.

［6］ Zi?tkiewicz E, Nitka B, Voelkel K, et al. Population specificity of the DNAI1 gene mutation spectrum in primary ciliary dyskinesia (PCD)［J］. Respir Res, 2010, 11(1): 174.

［7］ Guichard C, Harricane MC, Lafitte JJ, et al. Axonemal dynein intermediate-chain gene (DNAI1) mutations result in situs inversus and primary ciliary dyskinesia (Kartagener syndrome)［J］. Am J Hum Genet, 2001, 68(4):1030-1035.

［8］ Yang Z, Li H, Wang Z, et al. Microarray expression profile of long non-coding RNAs in human lung adenocarcinoma［J］. Thorac Cancer, 2018, 9(10): 1312-1322.

［9］ Wu HY, Wang XH, Liu K. LncRNA MALAT1 regulates trophoblast cells migration and invasion via miR-206/IGF-1 axis［J］. Cell Cycle, 2019, 19(1): 39-52.

［10］ Boyle TA, Quinn GP, Schabath MB, et al. A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses［J］.Cancer Med, 2020, 9(1):225-237.

［11］ Kibirova A, Mattes MD, Smolkin M. The journey of an EGFR-mutant lung adenocarcinoma through Erlotinib, Osimertinib and ABCP immunotherapy regimens: sensitivity and resistance［J］. Case Rep Oncol, 2019, 12(3): 765-776.

［12］ Kinoshita F, Takada K, Yamada Y, et al. Combined evaluation of tumor-infiltrating CD8+ and FoxP3+ lymphocytes provides accurate prognosis in stage IA lung adenocarcinoma［J］. Ann Surg Oncol, 2020, 27(6):2102-2109.

［13］ Satar NA, Fakiruddin KS, Lim MN, et al. Novel triple-positive markers identified in human non-small cell lung cancer cell line with chemotherapy-resistant and putative cancer stem cell characteristics［J］. Oncol Rep, 2018, 40(2): 669-681.

［14］ Liu ZhJ, Dou LT, Zhuang Zh, et al. Screening and survival analysis of differentially expressed genes in papillary thyroid carcinoma［J］. Acta Anatomica Sinica, 2020,51(1),51-57. (in Chinese)

刘中娇,窦龙涛,庄振,等.乳头状甲状腺癌差异表达基因的筛选及生存分析［J］. 解剖学报,2020,51(1):51-57.

［15］ Lu DY, Qu RX, Lu TR. Cancer bioinformatics for updating anticancer drug developments and personalized therapeutics［J］. Rev Recent Clin Trials, 2017, 12(2): 101-110.

［16］ Papaleo E, Gromova I. Gaining insights into cancer biology through exploration of the cancer secretome using proteomic and bioinformatics tools［J］. Expert Rev Proteomics, 2017, 14(11): 1021-1035.

［17］ Shao Y, Liang B, Long F, et al. Diagnostic microRNA biomarker discovery for non-small-cell lung cancer adenocarcinoma by integrative bioinformatics analysis［J］.Biomed Res Int, 2017, 2017(1):2563085.

［18］ Cheung CHY. Quantitative proteomics in lung cancer［J］. J Biomed Sci, 2017, 24(1):37.

［19］ Li X, Tian M, Peng B, et al. Mucin 16 regulating activity and migration of gallbladder cancer cells through phosphoinositide 3-kinase/protein kinase B pathway［J］. Acta Anatomica Sinica, 2019,50(5):613-619. (in Chinese)

李新,田蜜,彭冰,等.黏蛋白16基因通过磷酸肌醇3-激酶/蛋白激酶B通路调节胆囊癌细胞活力和迁移［J］.解剖学报,2019,50(5):613-619.

［20］ Liu J, Harada BT, He C. Regulation of Gene Expression by N6-methyladenosine in Cancer［J］. Trends Cell Biol, 2019, 29(6):487-499.

［21］ Emiraliogˇlu N, Ta?kran EZ, Ko?ukcu C, et al. Genotype and phenotype evaluation of patients with primary ciliary dyskinesia: First results from Turkey［J］. Pediatr Pulmonol, 2020, 55(2):383-393.

［22］ Zhang Y, Chen LA, Tian Q, et al. Expression differences of axonemal dynein gene DNAI1 of airway between smokers and non-smokers［J］. Chiinese Journal of Clinical Rehabilitation, 2004(12):2284-2285. (in Chinese)

张郁,陈良安,田庆,等.吸烟与非吸烟者气道纤毛轴动力蛋白基因DNAI1的表达差异［J］.中国临床康复,2004(12):2284-2285.